Understanding the Role of DNMT1 SUMOylation in Acute Myeloid Leukaemia
Grant number: 2003909 | Funding period: 2021 - 2023
Completed
Abstract
Most cancers have abnormally high levels of DNA methylation, which turns off cell death genes, making cancer cells immortal. We have a new drug, called DNMT1i, that targets this feature of cancer cells and we recently found a new drug target that enhances the activity of DNMT1i. Our research will determine how these two drugs synergise to effectively kill cancer cells and will justify their use in clinical trials, which we believe will improve outcomes for patients with cancer.